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Abstract
Risk of cardiovascular (CV) disease is increased among RA patients. High inflammatory burden associated
with RA appears to be a key driver of the increased cardiovascular risk. Inflammation is linked with
accelerated atherosclerosis and associated with a paradoxical inversion of the relationship between CV
risk and lipid levels in patients with untreated RA, recently coined the lipid paradox. Furthermore, the
inflammatory burden is also associated with qualitative as well as quantitative changes in lipoproteins, with
the anti-inflammatory and atheroprotective roles associated with high-density lipoprotein cholesterol sig-
nificantly altered. RA therapies can increase lipid levels, which may reflect the normalization of lipids due
to their inflammatory-dampening effects. However, these confounding influences of inflammation and RA
therapies on lipid profiles pose challenges for assessing CV risk in RA patients and interpretation of
traditional CV risk scores. In this review we examine the relationship between the increased inflammatory
burden in RA and CV risk, exploring how inflammation influences lipid profiles, the impact of RA therapies
and strategies for identifying and monitoring CV risk in RA patients aimed at improving CV outcomes.
Key words: rheumatoid arthritis, cardiovascular disease, inflammation, atherosclerosis, dyslipidaemias, anti-
rheumatic agents.
Introduction
It is now well established that RA is associated with in-
creases in both morbidity and mortality compared with the
general population. RA increases the risk of cardiovascu-
lar (CV) mortality by up to 50% compared with the general
population [13] and CV disease (CVD) is the leading
cause of death in RA patients [1, 49]. Large retrospective
studies of RA patients have shown the risk for myocardial
infarction (MI), adjusted for CV risk factors, to be
increased by up to 2-fold compared with control groups
[4, 10]. Two recent studies found that the increased risk of
CVD in RA is comparable to that observed for patients
with type 2 diabetes [11, 12]. Notably, the pattern of
CVD in RA patients appears to differ from that in the gen-
eral population; RA patients are more likely not only to
have silent ischaemic heart disease and experience
sudden death, but also to develop heart failure and die
shortly thereafter [9].
Traditional CV risk factors, such as hypertension, smok-
ing and type 2 diabetes, certainly contribute to the
increased risk of mortality in RA patients, but do not
fully explain it [13, 14]. Rather, the high systemic inflam-
matory burden associated with RA appears to be a key
driver of increased CV risk [1, 15]. The heightened inflam-
matory state in RA is linked to accelerated atheroscler-
osis, with systemic inflammation exacerbating adverse
changes in both established and novel CV risk factors
[1519]. Growing evidence suggests this excessive in-
flammatory burden is accountable for the lipid paradox
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in RA, in which cholesterol—an important CV risk factor in
the general population—is inversely related to CV risk in
patients with untreated RA [20, 21]. In contrast, suppres-
sion of RA-associated inflammation coincides with some
increases in lipid values, but also a reduction in CV events
[2124].
In light of this, the European League Against
Rheumatism (EULAR) recommendations for the manage-
ment of CV risk in RA highlight the critical importance of
adequate disease control in lowering CV risk. Annual CV
risk assessments are recommended for patients with RA,
with the risk assessment repeated when DMARD therapy
is changed [1]. Although the EULAR recommendations
have further helped to raise awareness of increased CV
risk in patients with inflammatory arthritis, evidence sug-
gests that these recommendations are not being prac-
tised either consistently or regularly [25, 26]. In addition,
the recommendations may also underestimate the overall
CV risk [27, 28].
In this review we examine the relationship between the
increased inflammatory burden in RA and CV risk, explor-
ing how inflammation influences lipid profiles and the
impact of RA therapies on lipoproteins. Furthermore, we
review the evidence and discuss strategies for identifying
and monitoring CV risk in RA patients, with the aim of
improving CV outcomes.
Inflammatory burden and CV risk in RA
Inflammation has consistently been shown to be a major
CV risk factor and there is now substantial evidence to
suggest that reducing inflammation lowers CV risk in RA
[2933]. Thus, compared with the general population, the
increase in CV events in RA appears to be a feature of the
systemic inflammation associated with RA disease activ-
ity. In this regard, the application of traditional CV risk
factor assessment equations, such as Framingham and
the Systematic Coronary Risk Evaluation (SCORE)
models, to patients with RA are reported to underestimate
their risk, as they do not fully incorporate the impact of
systemic inflammation and the confounding influence of
inflammation on lipid profiles [13, 25, 26, 28]. Even with
the application of a multiplier of 1.5 (recommended by the
EULAR) for patients with RA who meet two of three criteria
consisting of (i) a disease duration >10 years, (ii) RF or
anti-CCP positivity and (iii) the presence of severe extra-
articular manifestations, this modified SCORE (mSCORE)
may still result in a substantial proportion of RA patients at
high risk for CVD remaining unidentified [2628, 34].
Pivotal role of inflammation in the pathophysiology of
CVD in RA
A broad body of evidence indicates that inflammation
contributes to the onset and pathogenesis of atheroscler-
osis and CVD in the general population [3537].
Epidemiological studies suggest that a number of pro-in-
flammatory molecules, such as CRP, fibrinogen and cyto-
kines, are involved in mediating this process [3840].
Levels of these pro-inflammatory molecules and cytokines
are increased in RA patients; they not only promote
endothelial dysfunction and structural vessel abnormal-
ities, but also induce other CV risk factors, such as
changes in lipid levels, insulin resistance and oxidative
stress [4143]. Indeed, in RA, many studies have demon-
strated a significant association between inflammatory
measures, particularly ESR, and the risk of CVD [21,
4451].
Inflammation underlies the accelerated
atherosclerosis in RA
Inflammation contributes to all stages of atherosclerosis,
from plaque formation to instability and eventual plaque
rupture [5, 43, 52]. Atherosclerosis and RA share many
common inflammatory pathways, and the mechanisms
leading to synovial inflammation are similar to those
found in unstable atherosclerotic plaque [39, 43, 52]. For
example, the high levels of TNF, IL-6 and IL-1 associated
with RA are also central to the development of athero-
sclerosis [53, 54]. Indeed, IL-6 has been shown to be sig-
nificantly associated with atherosclerosis in RA patients,
independent of known CVD risk factors [55].
Furthermore, acute phase reactants (APRs), typically
elevated in RA, have been shown to be associated with
subclinical atherosclerosis, indicated by increased carotid
artery intimamedia thickness (cIMT) [56] and CV morbid-
ity and mortality in patients with RA [57]. In the general
population, CRP level is an independent predictor of CV
risk, particularly MI [58], while in both RA patients and
healthy subjects, CRP is associated with the number of
atherosclerotic plaques and cIMT [49, 59]. Notably, higher
IL-6 levels are also associated with increased mortality in
patients with acute coronary syndromes [60] and with
increased risk of future MI in healthy men [61]. Two
recent large-scale genetic and biomarker studies have
identified IL-6 receptor (IL-6R) signalling as having a
causal role in the development of coronary heart disease
(CHD), suggesting that IL-6R blockade could be con-
sidered a potential therapeutic approach for the preven-
tion of CHD [62, 63].
The impact of inflammation on dyslipidaemia in RA
In RA, inflammation is associated with a paradoxical in-
version of the usual relationship between CV risk and lipid
levels [21, 29, 64]. A similar inverse relationship has also
been observed with other chronic inflammatory diseases,
in sepsis, in cancer and in the immediate post-MI setting,
where increased CRP is associated with lower levels of
circulating lipids (Fig. 1) [6569]. This relationship has also
been noted in the period immediately after surgery, where
an inverse association has been observed between IL-6
elevation and cholesterol level [70]. Importantly, several
studies have reported increases in lipid levels with a suc-
cessful reduction in RA disease activity following anti-
inflammatory treatment [71]. These observations imply
that the traditional interpretation of lipid profiles for pre-
dicting CV risk in the general population may be con-
founded by disease activity in RA patients [21, 29].
The mechanisms by which the inflammatory process
can lead to these lipid changes are not fully understood,
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but may include suppression of the reticuloendothelial
system and reduced low-density lipoprotein (LDL) particle
synthesis [29]. It is possible that under high inflammatory
burden, excessive APR production may impair trafficking
of cholesterol in the liver or impede normal cholesterol
production. Additionally, CRP mediates the uptake of
LDL and oxidized LDL by macrophages, induces LDL
deposition and increases LDL uptake by hepatocytes
[72, 73].
The inflammatory burden in RA is associated with quali-
tative as well as quantitative changes in lipoproteins
[74]. High-density lipoprotein (HDL) has numerous anti-
inflammatory and atheroprotective roles, promoting re-
verse cholesterol transport from circulation to the liver
and preventing LDL oxidation [75]. This protective function
may be impaired during pathological processes that ac-
celerate CV events [7681]. Proteomic studies have found
that the subfraction composition of HDL isolated from RA
patients was significantly altered, with the resultant loss of
anti-inflammatory and reverse cholesterol transport func-
tion (summarized in Fig. 2) [74, 82, 83]. Other work has
suggested that the anti-inflammatory nature of HDL may
be a more sensitive marker of CVD than absolute HDL
levels. A good example of this comes from studies of
the cholesterol ester transfer protein inhibitors, dalcetra-
pib and torcetrapib, in which circulating HDL levels were
increased by as much as 3070%, yet no additional
cardioprotective effect was observed [84, 85]. Taken to-
gether, these findings indicate that both quantitative and
qualitative changes need to be considered when assess-
ing lipid profiles in RA [8688].
Impact of anti-rheumatic therapies on lipid profiles
and CV risk in RA
Traditional DMARDs
Traditional DMARDs, such as MTX, SSZ and HCQ, have a
protective role against CV risk [30]. The mechanisms by
which DMARD use influences CV risk are poorly under-
stood, but lend support to the hypothesis that reducing
inflammation is important in reducing CV risk. Of the trad-
itional DMARDs, MTX is the most widely used and is
known as the anchor drug in RA [89], yet the mechanisms
underlying its anti-inflammatory properties are not fully
understood [90]. MTX increases total cholesterol (TCh),
LDL, HDL and triglyceride levels in RA [91, 92].
However, it is believed that these changes are likely to
be due to the inflammatory-dampening effect of the
drug and may essentially reflect normalization of the
lipid levels to those seen in the general population [93].
These lipid increases are therefore not generally believed
to increase CV risk. On the contrary, there is evidence
from systematic reviews and large observational studies
that MTX therapy may decrease CV morbidity and mor-
tality in RA patients, although findings should be inter-
preted with caution given potential confounding by
issues of missing data, channelling and bias [9496].
Potential mechanisms of CV risk reduction with MTX are
also not well understood [57, 94], although suppression of
inflammation is likely to partially explain the perceived
cardioprotective effects of MTX. Currently, in the CV
Inflammation Reduction Trial, low-dose MTX (1520 mg/
week) is being tested to determine whether inhibition of
FIG. 1 Representation of the inverse relationship between
changes in inflammatory and lipid parameters
The paradigm by which an increase in the inflammatory
burden in RA is associated with the lowering of lipid levels
has also been noted in other chronic inflammatory con-
ditions, after MI, after surgery and in cancer treatment [21,
29, 6470]. In RA, a reduction of inflammation through
treatment with traditional and/or biologic DMARDs is
reflected in elevations in lipid levels [71]. Data, although
limited, suggest the extent to which lipid levels change
may be different between RA therapies; however, further
studies are required to fully ascertain the relationship
between suppression of inflammation, lipid elevations
and future cardiovascular risk [71, 102]. MI, myocardial
infarction.
FIG. 2 Inflammation induces qualitative changes to HDL
subparticle composition
Systemic inflammation associated with RA may confer
both quantitative and qualitative changes to HDL choles-
terol underlying the loss of some anti-inflammatory and
atheroprotective properties. Known changes to subparti-
cle composition induced by inflammation are summarized
in this figure [74, 7683, 8688]. apoA1: apolipoprotein A1;
apoJ: apolipoprotein J; CETP: cholesteryl ester transfer
protein; HDL: high-density lipoprotein; LCAT: lecithin
cholesterol acyltransferae; LDL: low-density lipoprotein;
PAF-AH: platelet-activating factor acetylhydrolase;
PON-1: paraoxonase 1; SAA: serum amyloid A; sPLA2:
secretory non-pancreatic phospholipase A2.
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inflammation per se improves CVD outcomes (clinical-
trials.gov, identifier NCT01594333). The outcome of this
study will be pivotal, as a positive finding would strongly
support the inflammatory hypothesis of atherothrombosis
and further establish inflammation as a key driver of CV
events [97].
Biologic agents: TNF inhibition
TNF, a pivotal cytokine in chronic inflammation, also af-
fects lipid metabolism, insulin resistance and endothelial
function [98, 99]. Anti-TNF therapy reduces inflammation,
including levels of CRP and ESR [100, 101], modifies the
lipoprotein spectrum and, in combination with MTX or
DMARDs, has been associated with a reduction of CV
risk in RA patients [3133]. Meta-analyses indicate that
anti-TNFs are generally associated with significant in-
creases in HDL, TCh and triglycerides in RA [71, 102],
but a recent study also suggests that anti-TNF therapy
may significantly increase LDL [103]. Notably, most stu-
dies demonstrate that the lipid ratio, TCh:HDL, is not ap-
preciably altered by anti-TNF therapy, or that increases
are modest (425%) [29]. Although these studies were
generally small and/or post hoc, a clear overall trend
was observed for increased circulating lipid levels with
anti-TNF therapy. Again, this may reflect a normalization
of lipid levels to the level prior to RA disease, and although
increases in triglycerides appear to be greater than those
observed with MTX, this may be due to more profound
suppression of inflammation with anti-TNFs [91].
Despite increases in lipid levels, systematic reviews
have consistently found an association between anti-
TNF therapy and a decreased risk of CV morbidity in RA
[104, 105], with an overall 54% reduction in risk of all CV
events [105]. A less definite association has been seen for
risk of the individual events of MI, stroke and heart failure,
but these analyses may have been confounded by com-
parisons with patients receiving other DMARDs, including
MTX, known to be associated with a decreased risk of
CVD [94, 104].
Interestingly, several studies have found that the level of
response to anti-TNFs may be important, with responders
having a significantly lower risk of CV-related events rela-
tive to non-responders [31, 104]. Although studies have
generally been small and beset with some methodo-
logical issues, anti-TNF therapy has been shown to
modify other factors associated with atherosclerotic
CVD risk in RA, including reductions in endothelial dys-
function [106109], enhancement of HDL anti-oxidative
capacity [110] and improvements in insulin sensitivity
[99]. Larger studies are required to confirm these findings.
Additionally, it is not yet known whether the impact of
anti-TNFs on lipid profile and CV risk is a class effect of
all anti-TNFs.
Biologic agents: IL-6R inhibition
Tocilizumab inhibits IL-6 signalling via the blockade of
IL-6R, resulting in a strong and sustained impact on in-
flammation, with rapid normalization of CRP and ESR
[111114]. Studies have consistently shown that tocilizu-
mab is associated with increasing lipid levels in the
context of decreasing levels of inflammatory markers
[111, 113, 115119]. However, these elevations have
been shown to respond to lipid-lowering therapies [120].
The mechanisms by which tocilizumab increases lipids
are not yet fully understood, particularly since polymorph-
isms of the IL-6R-yielding functional variants appear to
have no effect on lipid concentrations but do increase
levels of circulating IL-6 while reducing levels of APRs
[62, 63].
Importantly, similar to anti-TNF therapy, all main
lipoproteins—HDL, TCh, LDL and triglycerides— are
increased with tocilizumab treatment and are related to
relatively stable LDL:HDL and TCh:HDL ratios. These
ratios are known to be more closely associated with CV
risk than individual lipid measures, which can be con-
founded by the effect of inflammation [35, 121, 122]. The
ratio of apolipoprotein (apo) B:apoA1, which has been
shown to predict CV risk more accurately than any other
cholesterol index, remained stable over 6 months of toci-
lizumab treatment [113, 123, 124].
In the double-blind phase IV Adalimumab Actemra
(ADACTA) study, which evaluated tocilizumab monother-
apy vs adalimumab (anti-TNF) monotherapy in RA patients
intolerant to MTX or for whom continued MTX was
deemed inappropriate, more patients in the tocilizumab
group than in the adalimumab group had increased LDL
along with significantly greater reductions in CRP, ESR,
28-joint DAS (DAS28) and other composite measures of
disease activity at 24 weeks [125]. Qualitative changes in
lipid subfractions with tocilizumab therapy have been
examined in the placebo-controlled MEASURE study (a
randomized, parallel-group, open-label, multicentre
study to evaluate the effects of tocilizumab on vaccination
in subjects with active RA receiving background MTX),
which found that tocilizumab + MTX did not increase the
concentration of small, dense LDL particles, which are
generally believed to be pro-atherogenic [35, 126128],
compared with MTX alone at 12 or 24 weeks [129]. In
contrast, small and medium HDL particles, considered
to be anti-atherogenic, were significantly increased with
tocilizumab. Interestingly, the study also demonstrated
significant changes in paraoxonase 1 levels, HDL-asso-
ciated serum amyloid A (SAA) and secreted group IIA
phospholipase A2 (sPLA2-IIa) with tocilizumab, suggesting
that treatment alters HDL composition from a pro-inflam-
matory state to a less inflammatory state.
Data from the tocilizumab clinical development pro-
gramme and long-term extension studies provide some
reassurance for the lack of a negative effect of lipid profile
changes seen with tocilizumab on CV risk. In the double-
blind phase of the five core phase III studies of tocilizu-
mab, rates of MI were numerically lower with both doses
of tocilizumab vs controls [120], while analysis of the long-
term safety of tocilizumab (n= 4171; median treatment
duration 3.9 years) demonstrated a stable rate of CV
events over time with tocilizumab exposure [120, 130].
These clinical data are supported by imaging studies
that show that tocilizumab does not appear to increase
cIMT [131, 132].
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Interpretation of the effects of tocilizumab on inflam-
matory burden using only CRP or composite disease
activity measures that incorporate an APR component
can be misleading due to the powerful effect of IL-6
inhibition on hepatic APR production [133, 134].
However, in the ADACTA study, tocilizumab induced
not only a greater reduction in ESR and CRP at all
time points compared with adalimumab, but also a
greater reduction in the Clinical Disease Activity Index
(CDAI), which does not include an APR component
[125]. Interestingly, increased CRP levels have also
been established as a precursor of insulin resistance
development, an important CV risk factor, and a
recent subanalysis of the TOWARD (Tocilizumab in
Combination With Traditional DMARD Therapy) study
found that tocilizumab significantly improved insulin re-
sistance in RA patients [135, 136]. ENTRACTE, an on-
going randomized, open-label study evaluating the rate
of CV events with tocilizumab vs etanercept in patients
with RA, will provide further insight on the effects of
tocilizumab compared with anti-TNFs (clinicaltrials.gov
identifier NCT01331837).
Other RA therapeutic agents
Relatively little is known regarding the impact of other bio-
logics (rituximab, abatacept or anakinra) on lipid profiles
or CV risk in RA. Analyses of rituximab safety have
demonstrated no notable differences vs placebo in CV
event rates at 6 months and no evidence for an increased
association between MI and rituximab in longer-term
follow-up [137]. A recent analysis suggests rituximab
has beneficial effects on the cholesterol profile and alter-
ation of HDL to a less pro-atherogenic composition
during 6 months of treatment [82]. Rapid rituximab-
induced improvements in flow-mediated dilatation and
decreases in cIMT, coinciding with decreases in TCh
and increases in HDL, have also been demonstrated in a
small study [138].
Tofacitinib, an oral Janus kinase inhibitor, has recently
been approved by the US Food and Drug Administration
(FDA) as an RA medication. Lipid profile changes with
tofacitinib appear to be similar to those observed with
tocilizumab, with increases in both LDL and HDL, how-
ever, CRP does not appear to be reduced to the same
extent [139142]. In a phase III study, LDL and HDL levels
increased to a greater extent with tofacitinib than with the
anti-TNF adalimumab at 3 months, despite a numerically
similar impact on measures of disease activity—indicating
that there may be mechanisms involved other than
dampening of inflammation with tofacitinib [139]. A tofa-
citinib phase II study including co-administration of the
lipid-lowering agent atorvastatin indicated that the in-
crease in LDL and TCh could be reduced to below base-
line levels [143]. Analysis of major adverse CV events in
the tofacitinib clinical development programme demon-
strated a similar incidence across groups in the phase III
programme, with lower rates in long-term extension stu-
dies, suggesting no increased CV risk over 3 years of
follow-up [144].
Management of lipid profiles and CV risk in RA
Given the high level of systemic inflammatory burden that
characterizes RA, which is regarded as a key CV risk
factor, alongside an increased prevalence of traditional
risk factors, EULAR recommendations highlight the im-
portance of adequate disease control in order to lower
CV risk (Table 1) [1]. The vulnerability of the carotid
plaque has been shown to be influenced by RA disease
activity, and remission may alleviate this threat [145].
Therefore effective CV risk management will likely com-
prise not only adequate treatment of conventional risk fac-
tors, but also tight and sustained disease activity control
[27]. The complex impact of inflammation on lipid particle
composition as well as the phenomenon of the lipid para-
dox in RA makes interpretation of circulating lipid levels
difficult, potentially limiting their usefulness as a marker of
CV risk [21, 29]. Moreover, in a post hoc analysis from the
Apolipoprotein-related Mortality Risk (AMORIS) study, the
association between TCh and acute MI was found to be
weaker among patients with RA than the general popula-
tion [10]. This may suggest that the traditional interpret-
ation of hypercholesterolaemia as a risk for CVD may not
apply and that lipid levels from RA patients may be a con-
founding factor in CV risk algorithms.
The potent suppression of inflammation with biologic
therapies in RA is accompanied by increases in lipid par-
ameters that are normally associated with increased CV
risk in the general population. Thus, in order to appropri-
ately manage lipid levels in RA patients, it is advisable to
reassess the lipid profiles of patients after dampening in-
flammation. Strategies such as treat-to-target, with dis-
ease remission or low disease activity as the clinical
goal, as soon as RA is diagnosed can be highly effective
to rapidly reduce inflammation and achieve tight control of
disease activity (an overview of the benefits of dampening
inflammation on CV risk in RA is shown in Fig. 3) [146].
Lipid profiles can then be monitored and, if appropriate,
treated with lipid-lowering drugs according to national
guidelines [147149].
The EULAR recommendations for CV management,
based on a systematic literature review and the opinion
of an interdisciplinary task force, are a highly welcome
starting point for identifying and improving the manage-
ment of CV risk in patients with RA. Although it was
acknowledged by the EULAR task force that their ap-
proach was conservative, evidence suggests that, even
after applying the multiplication factor, the mSCORE risk
factor equation may still not accurately estimate CV risk
for individual RA patients [26, 27, 150]. One aspect poten-
tially contributing to this underestimation of risk is the use
of a disease duration >10 years as a criteria for increased
CV risk, as most evidence now supports increased risk of
CVD early in disease [151153]. Thus more discriminating
tools for identifying RA patients with higher risk of CVD
are needed.
Several validated non-invasive imaging techniques are
now available for determining subclinical atherosclerosis
in RA [34, 154, 155]. Of these, ultrasonographic assess-
ment of cIMT and the presence of plaques has been
www.rheumatology.oxfordjournals.org 2147
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identified as useful for stratifying RA patients with high CV
risk [34, 56, 149]. In a recent study 60% of patients
identified as having moderate CV risk according to the
mSCORE had evidence of carotid plaques and/or cIMT
>0.90 mm (both considered factors indicative of CV prog-
nosis in the general population) [34]. Furthermore, the pro-
portion of patients identified as having high or very high
CV risk increased from 9.2% with the mSCORE to 47.7%
with additional carotid US results [27, 34]. Non-invasive
imaging techniques such as carotid ultrasonography
may thus be useful alongside CV risk assessment
models to enhance the identification of RA patients with
increased CV risk. However, the feasibility of performing
these assessments within a rheumatology clinic or in part-
nership with a specialist cardiology clinic needs to be es-
tablished [27].
Conclusion
The CV risk in RA is increased to a similar magnitude to
that seen in type 2 diabetes and is related to the systemic
inflammatory burden associated with RA as well as an
increased prevalence of traditional risk factors. Anti-
rheumatic therapies that are highly effective at reducing
inflammation appear to increase TCh and LDL levels, al-
though in light of the lipid paradox in RA, the benefits of
suppression of inflammation are likely to outweigh lipid
changes that might otherwise be considered to be ad-
verse. In this regard, the suppression of inflammation
through tight and sustained disease control is important
for lowering CV risk, but also to permit accurate screening
of patients at high CV risk.
The optimal approach for identification of patients with
increased CV risk has yet to be fully established, but it
is key that (i) all RA patients be screened and (ii) the
appropriate management for those who are at high
risk be undertaken. Current assessment tools and
TABLE 1 Ten recommendations from EULAR for CV risk management in RA
1 RA should be regarded as a condition associated with higher risk for CV disease. The increased risk appears to be due
to both an increased prevalence of traditional risk factors and the inflammatory burden.
2 Adequate control of disease activity is necessary to lower the CV risk.
3 CV risk assessment using national guidelines is recommended for all patients with RA. Risk assessments should be
repeated when anti-rheumatic treatment has been changed.
4 Risk score models should be adapted for patients with RA by introducing a 1.5 multiplication factor. This multiplication
factor should be used when the patient with RA meets two of the following three criteria:
(i) disease duration >10 years, (ii) RF or anti-CCP positivity and (iii) the presence of certain extra-articular
manifestations.
5 TCh/HDL cholesterol ratio should be used when the SCORE model is used.
6 Intervention should be carried out according to national guidelines.
7 Statins, ACE inhibitors and/or AT-II blockers are preferred treatment options.
8 The role of coxibs and most NSAIDs in CV risk is not well established and needs further investigation. Hence we should
be very cautious about prescribing them, especially for patients with a documented CV disease or in the presence of
CV risk factors.
9 Corticosteroids: use the lowest dose possible.
10 Recommend smoking cessation.
CV: cardiovascular; coxibs: cyclooxygenase (COX) inhibitors; TCh: total cholesterol; HDL: high-density lipoprotein cholesterol;
ACE: angiotensin-converting enzyme. Adapted from Peters et al. [1].
FIG. 3 Impact of tight control of inflammation and disease
activity in relation to the reduction of cardiovascular risk
in RA
The heightened inflammatory state in RA is linked with
accelerated atherosclerosis, with systemic inflammation
exacerbating adverse changes in both established
and novel cardiovascular (CV) risk factors [1619].
Additionally, the use of some anti-inflammatory medica-
tion is also associated with increasing CV risk [6].
Treat-to-target strategies with traditional and/or biologic
DMARDs can be highly effective to rapidly reduce in-
flammation and achieve tight control of disease activity
[146]. Lipid profiles can then be monitored and, if appro-
priate, treated with lipid-lowering drugs according to
national guidelines [147149].
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recommendations may underestimate CV risk in some pa-
tients. The use of non-invasive imaging tools may help to
improve the sensitivity of CV assessments, but further re-
search is needed to assess the feasibility of incorporating
these techniques into routine practice.
Rheumatology key messages
. Inflammation in RA is associated with a paradoxical
inversion of the relationship between cardiovascular
risk and lipid levels.
. Increases in lipid levels by RA therapies reflect nor-
malization of lipids due to their inflammatory-
dampening effects.
. More discriminating tools for identifying RA patients
with a higher risk of cardiovascular disease are
needed.
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